

July 8, 2020

Unprecedented quarter depicts FMCG resilience...

Q1FY21 has been an unprecedented quarter with the lockdown impacting manufacturing & supply chain operations for a large part of the quarter. Though supply side issues were temporary, the demand pattern could have lasting impact on some categories. Moreover, new trends have emerged in the last three months, which would aid the growth prospects of some companies in our coverage universe. We observed two broad trends during the quarter. The surge in demand for categories like atta, biscuits, edible oil, and salt is temporary given consumers stock up essential either before or during lockdown period. However, growth in categories like soaps, sanitisers, immunity boosting products (Chyawanprash, Honey), some packaged foods categories (shift in pulses from loose to package) could be structural in nature.


With the consolidation of acquired companies' revenue for HUL, Tata Consumer Product, the numbers are not comparable. We estimate 10.6% revenue decline for our coverage companies largely impacted by a significant dip in cigarette companies (ITC, VST Industries) revenues. Cigarette companies witnessed the biggest dent in the lockdown period with sales loss for 40-45 days during the quarter. Further, these companies recovered volumes to pre-Covid-19 levels only in mid-June. Hence, we estimate ~50% drop in cigarette volumes during the quarter.


Other FMCG companies restarted manufacturing only in the second half of April but permission to start plant largely depended on essential & nonessential categories. Manufacturing facilities producing packaged foods, hygiene products (soaps, sanitisers) started early (within 10 days of lockdown) compared to products more discretionary (hair oil, skin care products, cosmetics) in nature. We expect 12-17% revenue decline for HUL (ex-acquisition), Dabur and Marico. Including the acquisition numbers for HUL, we expect a revenue decline of 2.4%.

Some categories like hair care, skin care, cosmetics, ice-creams have been adversely impacted during the quarter whereas soaps, sanitisers, edible oil, health supplement witnessed healthy growth. We expect foods companies like Nestle to remain largely unaffected by the lockdown as the company was able to refill the trade pipeline in June quarter with production coming back to normal. We expect Tata Consumer Products to post 10% revenue decline (ex-acquisition). However, including acquired business numbers, it is expected to report 27.5% growth in sales. Its revenues were impacted by multiple factors. The decline in out of home consumption of tea was partially offset by in-house increase in demand. We believe acquired salt & pulses business is likely to witness strong growth in April & May given stocking up by retailers & consumers.

Sequence from lockdown to unlocking

Most companies were able to fulfil April (as and when distribution starts) demand from existing March inventories at companies as well as at the distributor levels. With companies reaching only ~70% of the normal manufacturing by the start of May, the trade pipeline got depleted fast while companies were unable to fulfil the entire demand in May 2020. However, in June, production levels reached near 100% of pre-lockdown levels while companies were not only able to fulfil the month's demand but were also in a position to refill trade inventory at previous levels.





Copra price trend (₹/kg)

Operating margin trend (%)												
Company		EBITE	DA mar	gin %								
Company	Q1'20	0.2'20	0.3'20	Q4'20	Q1'21E							
Dabur	20.1%	22.1%	20.9%	18.9%	18.9%							
HUL	26.2%	24.8%	24.9%	22.9%	26.5%							
ITC	39.7%	38.4%	38.4%	36.5%	28.5%							
Marico	21.3%	19.3%	20.4%	18.9%	21.0%							
Nestle	23.2%	23.4%	21.5%	23.9%	24.7%							
Tata Cons	14.0%	12.8%	12.2%	12.8%	13.2%							
VST Ind.	37.8%	32.2%	31.5%	32.5%	21.2%							
FMCG	29.5%	28.7%	28.5%	27.0%	24.9%							

Top Picks


Dabur

Research Analysts

Sanjay Manyal sanjay.manyal@icicisecurities.com

ICICI Direct Research

Crude oil prices trend (\$/barrel)



Benign commodity cost offsets negative operating leverage

The sharp decline in crude based commodity prices is likely to reduce packaging cost for FMCG companies. This coupled with stable commodity prices are expected to result in an up-tick in gross margins (except Tata Consumer Products), which is expected offset the negative operating leverage impact on operating margins. Excluding ITC & VST, we expect similar margins (23.3%) for our coverage companies. Copra, palm oil & sugar prices have remained largely stable whereas milk prices, which were at elevated levels before lockdown, dipped sharply in April. However, tea prices rose ~20-40% in June with 140 million kg of lower production between January-June due to lower availability of labour. This would negatively impact operating margins for Tata Consumer Products & HUL's tea business. Our coverage universe net profit is expected to decline 16.3% largely impacted by a decline in ITC's earnings.

Exhibit 1: Estimates for Q1FY21E: (FMCG) (₹ crore)														
Company	Revenue	Change (%)		EBITDA	Char	nge (%)	PAT	Change (%)						
	Q1FY21E	YoY	QoQ	Q1FY21E	YoY	QoQ	Q1FY21E	YoY	QoQ					
Dabur India Ltd	1,887.6	-17.0	1.2	357.2	-21.9	1.4	286.2	-21.3	1.6					
HUL	9,872.8	-2.4	9.6	2,618.0	-1.1	26.8	1,892.9	7.9	24.6					
ITC	8,558.7	-25.6	-25.1	2,437.8	-46.6	-41.4	2,105.9	-33.7	-44.5					
Marico Ltd	1,860.9	-14.1	24.4	390.6	-15.3	38.5	279.8	-16.3	40.6					
Nestle India	3,188.8	6.3	-4.1	787.3	12.9	-0.8	502.7	14.8	-4.3					
Tata Consumer	2,418.0	27.5	0.5	319.9	20.8	3.7	167.5	18.2	LP					
VST Industries	152.3	-50.0	-47.8	32.3	-72.0	-65.9	24.7	-67.3	-65.0					
Total	27,938.9	-10.6	-6.3	6,943.1	-24.6	-13.8	5,259.6	-16.3	-16.1					


Source: Company, ICICI Direct Research

Exhibit 2:	Company Specific Views (FMCG)
Company	Remarks
Dabur	We expect Dabur to witness 17% sales decline in the June quarter as operations largely remained disrupted in April. Since then, it gradually returned to normal in June 2020. We believe juices would have been the worst impacted category by lockdown given Q1 is peak season for the category. Further, among discretionary category, hair oil segment would have also been negatively impacted. However, the company has started witnessing strong growth in immunity boosting products like Chyawanprash and Honey. We expect a 120 bps contraction in operating margins due to negative leverage despite an uptick in gross margins. PAT is likely to dip 21.3% during the quarter
HUL	HUL is likely to witness a revenue decline of 2.4% (including acquired company's sales). Though the company was able to start manufacturing in mid-April, it only reached the previous year's levels by June 2020. However, we believe HUL would have been able to refill the inventory at the distributor level by the end of June 2020, which would have absorbed some of the lost sales in April & May. On the demand front, we believe personal care (cosmetics) & ice-creams would have been severely impacted with a near washout quarter for both categories. However, soaps, sanitisers would have seen strong growth induced by increased consumer awareness about hygiene. We expect 12% & 13% revenue decline in home care & BPC (beauty & personal care) categories, respectively. With benign raw material cost, reduction in A&P spends and other cost cutting measures, we expect the company to maintain operating margins at 26.5% (35 bps higher). PAT is likely to grow 7.9% aided by profits from GSK acquisition & lower income tax

Source: Company, ICICI Direct Research

ICICI	Direct	Research

Crude oil price trend (\$/barrel)








Exhibit	3: Company Specific Views (FMCG)
	We expect ITC to post 25.6% decline in sales given the company lost 40-45 days of
	cigarettes sales, which is a permanent loss (it cannot be recovered with future sales).
	We expect 50% dip in cigarettes volumes during the quarter. The company had taken
	\sim 10% price hike after excise duty increase in Budget 2020. We expect 30% decline in
	agri & paper businesses revenues with supply chain remaining disrupted in April & May.
	Hotels business was the worst hit with occupancy dropping to single digits. We expect
ITC	80% decline in sales in a near washout situation. FMCG business would have been
	silver lining given most categories like atta, biscuits, packaged foods, soaps &
	sanitisers are part of the essentials & started manufacturing within 10-15 days of
	lockdown. Further, demand for packaged foods increased significantly given increased
	in-home consumption. Operating margins are likely to witness significant contraction
	due to negative operating leverage. We expect earnings to decline 33.7%

Marico is expected to post 14.1% decline in sales given parachute & VAHO production & distribution were negatively impacted in April & billing only started at the end of April. However, Saffola edible oil & foods portfolio witnessed strong growth with increase inhome consumption & growing preferences towards healthier food. Pantry sales declined
 Marico 50% during the quarter. We expect the company to maintain operating margins at 21% (30 bps lower) given significant dip in commodity prices, cut in media spends & other cost cutting measures. Net profit is likely to decline 11.3% to ₹ 279.8 crore

Nestlé is likely to witness 6.3% sales growth during the quarter as manufacturing & supply chain operations remain disrupted during the quarter. Given, large part of Nestlé's product portfolio is essentials (milk, infant food), the manufacturing in those plants started quickly. In the second half of April, the company was able to supply goods from the carry forward stock of March. However, the company struggle to fulfill some of the categories (noodles) demand in May. With the steep decline in commodity cost and reduction in A&P (promotions were largely withdrawn), operating margins are likely to perk up by 145 bps to 24.7%. We estimate earnings growth of 12.7%

Tata Consumer is likely to witness 27.5% revenue growth aided by inclusion of acquired consumer business of Tata Chemical. We believe acquired salt business would have witnessed a strong growth given increased stocking by consumers & retailers. Excluding the acquired business, revenue decline would have been ~10%. Tea prices sharply rose ~20-40% in June 2020 after 140 million kg production cut mainly impacted by lockdown. This would adversely impact gross margins. We expect operating margin contraction of 70 bps to 13.2%. With Starbucks stores closed for most of the quarter, loss from associates is expected to increase from ₹ 7.4 crore to ₹ 28 crore. Considering all these factors, we estimate net profit growth of 18.2% to ₹ 167.5 crore

 VST is expected to see 50% decline in sales with ~60% decline in volumes given no sales was booked for 40-45 days. The company took more than 10% price hikes after the excise increase in 2020 Budget. Further, manufacturing & distribution operations gradually returned to normal by June 2020. Operating margins are expected to dip sharply owning to the negative operating leverage. Net profit is expected to dip 67.3% to ₹ 24.7 crore

Source: Company, ICICI Direct Research

Canton / Commons	CMP	TP		M Cap		EPS (₹)			P/E (x)		Price/Sales (x)		(x)	RoCE (%)			RoE (%)		
Sector / Company	(₹)	(₹)	Rating	(₹ Cr)	FY20	FY21E	FY22E	FY20	FY21E	FY22E	E FY20	FY21E	FY22E	FY20	FY21E	FY22E	FY20	FY21E	FY22E
Colgate (COLPAL)	1,395	1,350	Hold	37,942	30.0	29.3	33.6	46.5	47.5	41.5	8.5	8.3	7.6	60.7	66.2	77.5	52.2	51.2	50.8
Dabur India (DABIND)	477	520	Buy	83,785	8.2	8.8	10.3	58.2	54.2	46.4	9.6	9.6	8.3	26.1	25.7	28.3	21.9	22.5	24.8
Hindustan Unilever (HINLEV)	2,158	2,250	Hold	507,235	31.2	33.5	41.3	69.2	64.3	52.2	13.3	12.6	0.0	82.5	24.4	30.3	85.7	20.2	25.0
ITC Limited (ITC)	197	250	Buy	239,304	12.5	11.6	13.6	15.8	17.0	14.5	5.2	5.4	4.7	29.4	28.0	30.9	23.8	21.5	23.7
Jyothy Lab (JYOLAB)	124	115	Hold	4,553	5.3	4.3	4.1	23.6	28.9	30.1	2.6	2.7	2.9	28.6	24.3	23.3	22.6	21.7	18.8
Marico (MARLIM)	352	300	Hold	45,415	8.1	7.8	9.5	43.5	44.9	37.2	6.2	6.5	5.5	41.0	40.1	46.9	34.5	33.8	40.3
Nestle (NESIND)	16,955	18,000	Hold	163,480	204.3	230.9	269.4	83.0	73.4	62.9	13.3	12.3	10.8	56.9	59.3	65.9	101.9	114.1	123.1
Tata Consumer Product (TATGLO)	432	440	Buy	39,809	5.0	8.7	10.9	86.5	49.8	39.7	4.1	3.9	3.6	6.9	7.9	8.8	4.6	5.9	7.1
VST Industries (VSTIND)	3,216	4,000	Buy	4,966	196.9	124.8	216.3	16.3	25.8	14.9	4.0	4.5	3.5	52.1	32.9	45.6	38.6	24.3	33.7
Varun Beverage (VARBEV)	685	580	Reduce	19,451	16.6	9.9	18.1	41.2	69.2	37.8	4.9	3.8	2.7	15.5	11.3	16.3	14.2	8.8	14.2
Zydus Wellness (ZYDWEL)	1,363	1,530	Buy	7,859	32.2	31.6	50.3	42.3	43.1	27.1	4.4	4.7	3.9	5.9	5.7	7.4	5.4	5.1	7.5

pankaj.pandey@icicisecurities.com

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15% Hold: -5% to 15%; Reduce: -15% to -5%; Sell: <-15%



Pankaj Pandey

Head – Research

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ICICI Securities | Retail Research

ANALYST CERTIFICATION

I/We, Sanjay Manyal, MBA (Finance) Research Analyst, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on vww.icicibank.com

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report may not be suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.